NIH: Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research
This grant supports early-stage development of innovative molecular or cellular analysis technologies aimed at improving cancer research. Projects must involve high-risk, high-impact innovations that advance methods for detecting, probing, or analyzing cancer-related biological processes. Technologies should have widespread applicability in cancer biology, detection, diagnosis, epidemiology, treatment, or health disparities research.
Eligibility Criteria:
-
U.S. and non-U.S. institutions of higher education
-
Nonprofits (with or without 501(c)(3) status)
-
For-profit organizations (small and large)
-
Government agencies (federal, state, tribal, local)
-
Foreign organizations and components
-
Individuals with relevant expertise may apply as PD/PI
-
No cost sharing required
-
Multiple applications allowed if scientifically distinct
Funding Details:
-
Funding Instrument: Grant
-
Activity Code: R61 (Exploratory/Developmental)
-
Total Available: $4.2 million (FY2026)
-
Expected Awards: 17
-
Budget Cap: $150,000/year in direct costs
-
Project Duration: Up to 3 years
-
No clinical trials allowed
Deadline:
-
Earliest Submission Date: March 4, 2025
-
Due Dates:
-
April 4, 2025
-
October 3, 2025
-
-
Letter of Intent: 30 days prior to the due date
-
Expiration Date: October 4, 2025
-
Submit by 5:00 PM local time of the applicant organization
Where to Go for Further Information:
-
FOA Number: RFA-CA-25-001
-
Full FOA: grants.nih.gov
-
Program Contact:
-
Kelly Crotty, Ph.D., NCI – [email protected]
-
-
Financial Contact:
-
Sean Hine, NCI – [email protected]
-
-
Application Portal: Grants.gov or NIH ASSIST
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023